文献速递糖尿病

磺脲类药物对心脏线粒体KATP通道亲和力与2型糖尿病主要不良心血管事件风险的关系

Association Between Specificity of Sulfonylureas to Cardiac Mitochondrial KATP Channels and the Risk of Major Adverse Cardiovascular Events in Type 2 Diabetes.
PubMed 文献 · Diabetes Care · 2022-01-01

基于台湾全民健康保险数据库的队列研究,纳入2007至2016年间起始磺脲类单药治疗的2型糖尿病患者,经1:1倾向评分匹配后比较心脏线粒体KATP通道高亲和力(格列本脲、格列吡嗪)与低亲和力(格列齐特、格列美脲)磺脲类各33,727例。高亲和力组三点主要不良心血管事件(MACE)风险显著升高(aHR 1.21,95%CI 1.03-1.44),缺血性卒中(aHR 1.23,95%CI 1.02-1.50)和心血管死亡(aHR 2.61,95%CI 1.31-5.20)风险亦升高,心肌梗死无显著差异(aHR 1.04,95%CI 0.75-1.46)。

要点

  • 心脏mitoKATP通道高亲和力磺脲类与三点MACE风险升高相关(aHR 1.21,95%CI 1.03-1.44)。
  • 高亲和力磺脲类与缺血性卒中(aHR 1.23,95%CI 1.02-1.50)和心血管死亡(aHR 2.61,95%CI 1.31-5.20)风险升高相关。
  • 高亲和力磺脲类与心肌梗死风险无显著相关(aHR 1.04,95%CI 0.75-1.46)。

核心结论

  • 在全国性糖尿病人群中,心脏mitoKATP通道高亲和力磺脲类相比低亲和力磺脲类与MACE风险升高相关。

研究设计与样本

  • 使用台湾全民健康保险数据库的队列研究,纳入2007至2016年间起始磺脲类单药治疗的2型糖尿病患者。
  • 经1:1倾向评分匹配后,心脏mitoKATP通道高亲和力(格列本脲和格列吡嗪)与低亲和力(格列齐特和格列美脲)磺脲类新用户各33,727例。
  • 采用Cox比例风险模型估计调整风险比(aHR)和95%CI。

主要发现

  • 高亲和力磺脲类与三点MACE风险显著升高相关(aHR 1.21,95%CI 1.03-1.44)。
  • 高亲和力磺脲类与缺血性卒中风险显著升高相关(aHR 1.23,95%CI 1.02-1.50)。
  • 高亲和力磺脲类与心血管死亡风险显著升高相关(aHR 2.61,95%CI 1.31-5.20)。
  • 高亲和力磺脲类与心肌梗死风险无显著相关(aHR 1.04,95%CI 0.75-1.46)。
  • 疗程-反应分析显示MACE风险在治疗90天内最高(aHR 4.67,95%CI 3.61-6.06)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Previous studies have revealed an intraclass difference in major adverse cardiovascular events (MACE) among sulfonylureas. In vitro and ex vivo studies reported several sulfonylureas to exhibit high-affinity blockage of cardiac mitochondrial ATP-sensitive potassium (mitoKATP) channels and could interfere with ischemic preconditioning, the most important mechanism of self-cardiac protection. However, no studies have examined whether these varying binding affinities of sulfonylureas could account for their intraclass difference in MACE. We compared mitoKATP channel high-affinity versus low-affinity sulfonylureas regarding the MACE risk in real-world settings. RESEARCH DESIGN AND METHODS: Using the Taiwan nationwide health care claims database, patients with type 2 diabetes initiating sulfonylurea monotherapy between 2007 and 2016 were included in the cohort study. A total of 33,727 new mitoKATP channel high-affinity (glyburide and glipizide) and low-affinity (gliclazide and glimepiride) sulfonylurea users, respectively, were identified after 1:1 propensity score matching. Cox proportional hazard models were used to estimate adjusted hazard ratios (aHRs) and 95% CI. RESULTS: MitoKATP channel high-affinity sulfonylureas were associated with a significantly increased risk of three-point MACE (aHR 1.21 [95% CI 1.03-1.44]), ischemic stroke (aHR 1.23 [95% CI 1.02-1.50]), and cardiovascular death (aHR 2.61 [95% CI 1.31-5.20]), but not with that of myocardial infarction (aHR 1.04 [95% CI 0.75-1.46]). The duration-response analyses revealed the highest MACE risk to be within 90 days of therapy (aHR 4.67 [95% CI 3.61-6.06]). CONCLUSIONS: Cardiac mitoKATP channel high-affinity sulfonylureas were associated with an increased MACE risk compared with low-affinity sulfonylureas in a nationwide population with diabetes.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Wang MT, Huang YL, Lai JH, et al. Association Between Specificity of Sulfonylureas to Cardiac Mitochondrial KATP Channels and the Risk of Major Adverse Cardiovascular Events in Type 2 Diabetes. Diabetes Care. 2022. PMID: 35294529. doi:10.2337/dc21-1779

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。